Colorectal cancer (CRC) is the most common gastric intestinal malignancies and remain a prime death causing cancer worldwide. Although recent advancements in surgical and multimodal treatments, overall survival rates for advanced CRC patients remain poor. Molecular and metabolic processes that have been shown to contribute to phenotypic alterations favoring cancer include: gene mutation, angiogenesis, development of benign lesion, enhanced carcinoma proliferation. These occurrences may have a role in the onset and progression of cancer (carcinogenesis). A biomarker is a chemical that may be detected in blood, stool and tissue samples to allow pathological diseases like cancer to be identified. As a result, finding accurate and useful molecular biomarkers to help in the diagnosis and treatment of CRC would be advantageous. This review is based on the available information from published research papers related to different biomarkers that are used in the diagnosis of colorectal cancer also take a quick glimpse into the future.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
